Dr. John Stone is the director of Clinical Rheumatology at Massachusetts General Hospital and professor of Medicine at Harvard Medical School. His work focuses on vasculitis, a group of inflammatory diseases that target blood vessels, as well as on a newly-described multi-organ condition known as IgG4-related disease (IgG4-RD).
Dr. Stone graduated from Harvard Medical School, completed his internal medicine training at Johns Hopkins University School of Medicine, and a rheumatology fellowship at the University of California-San Francisco. Before coming to Mass General, he co-founded and directed the Vasculitis Center at Johns Hopkins University.
Dr. Stone is the principal investigator in the Rituximab in ANCA-associated Vasculitis (RAVE) clinical trial, which led to two New England Journal of Medicine publications. The RAVE trial was the first trial to serve as the sole basis of approval by the U.S. Food and Drug Administration for a new use of this drug, changing the standard of care for this disease. Further regulatory approvals for Rituximab use in vasculitis are now anticipated in approximately 90 countries on the strength of this single trial.
Dr. Stone’s research group has also broadened knowledge of IgG4-RD, a condition unknown in the U.S. before Dr. Stone’s work. He has become the world’s leading investigator in this disease, and hosted the first two international symposia on this disease (Boston, 2011; Hawaii, 2014). He has assembled a creative research group to tackle this emerging condition, the study of which is revealing important insights into human immunology. The IgG4-RD Research Group at Mass General has identified key organ system manifestations of this disease and was the first to recognize the efficacy of B cell depletion as a treatment strategy. Finally, in studying patients with IgG4-RD, Dr. Stone’s group has identified a novel T lymphocyte that may drive the intractable condition of fibrosis across an array of human diseases.